Coverage: what public plans actually list
Public drug plan coverage for weight-loss medicines in Canada
What the public plan documents list for every province and territory, with the conditions, the document date and the depth of the evidence behind each record.
"Is it covered?" is several questions wearing one coat. This page keeps them apart and shows, for every province and territory, what the public plan documents actually list for semaglutide, for the weight-management products, and for Imcivree.
Nothing here is a benefit decision. A listing with criteria means a prescriber can apply; it does not mean a specific person qualifies. "Not found" means the researcher looked and did not find a listing, which is not the same as "not covered".
Seven things this record keeps separate
Each of these lives in its own field. One never fills in another.
- Authorized in Canada Health Canada has issued a Notice of Compliance and a DIN.
- Marketed status in the DPD The Drug Product Database says Marketed, Approved, Dormant or Cancelled. Approved is not Marketed.
- Actual pharmacy stock Always unknown on this site. Nothing here says a product is on a shelf.
- Canadian indication and age group What the product monograph authorizes, for whom. A US indication is not a Canadian one.
- Provincial public coverage Whether a public plan pays, under what criteria, from what date.
- Provincial interchangeability Whether a pharmacist may substitute a generic for the brand under that province's rules.
- Private insurance Not researched. Every plan differs.
What kind of coverage are you checking?
- Clinician fees. Provincial health insurance pays physicians and nurse practitioners for insured visits. Whether a private online service's visit is insured is a separate question that the service, not this site, must answer.
- Laboratory tests. Often insured when ordered by an insured clinician, but services and provinces differ.
- The drug, public plan. What this page documents. Public plans in Canada list semaglutide only for type 2 diabetes with criteria, and no province reviewed lists a product for chronic weight management, apart from Imcivree for two rare genetic conditions.
- The drug, private plan. Not researched. Plans differ; some run prior authorization with Wegovy-specific criteria. Ask your plan.
- Manufacturer support programs. Some displayed prices depend on one. Ask the provider what happens if you do not qualify.
The record, all thirteen jurisdictions
The depth tag says how deep the evidence goes: full (documents opened for status, criteria, interchangeability and price), moderate (listings and diabetes criteria opened; some fields unknown), programme-level only (plan pages read; no product list extracted).
This table scrolls sideways.
| Jurisdiction | Depth | Semaglutide for type 2 diabetes | Weight-management products | Imcivree (rare genetic obesity) | Interchangeability with Ozempic | Document date | Claims |
|---|---|---|---|---|---|---|---|
| British Columbia | full | Special Authority (diabetes) for Ozempic and the four Dr. Reddy's and Apotex generic DINs; SA form HLTH 5826 Rev 2026/02/13; criteria: T2D after inadequate control on maximally tolerated metformin; 1 mg weekly ceiling | Non-benefit: all Wegovy DINs, Saxenda, Victoza, Rybelsus. Wegovy weight/CVD decision Non-benefit 18 Dec 2025 (pCPA concluded without agreement 1 Dec 2025; Ministry will review generic semaglutide when marketed). No tirzepatide listing. | Imcivree through EDRD for BBS obesity, age 6 and up, decision 29 Jul 2025 | not extracted as a group list; generics listed individually under SA | PharmaCare formulary coverage data 2026-09-08; decision listing updated 2026-09-16 | A-C21 R21-C466 R21-C467 R21-C468 R21-C469 R21-C470 R21-C471 R21-C472 R21-C473 R21-C474 R21-C475 R21-C476 R21-C477 R21-C478 R21-C479 R21-C480 R21-C481 R21-C482 R21-C483 R21-C484 R21-C485 R21-C486 R21-C487 R21-C488 R21-C489 R21-C490 R21-C491 R21-C492 R21-C493 R21-C494 R21-C495 |
| Alberta | moderate | Step therapy / special authorization (diabetes) for Apotex and Dr. Reddy's generics; Aspen DINs shown as under review | No weight product found other than Imcivree | Imcivree SA for BBS obesity age 6 and up | Apo 02568012 and Dr. Reddy's 02567814 interchangeable with Ozempic 02471469; Dr. Reddy's 02567806 with Ozempic 02471477; Apo 02568020 not interchangeable; coverage update 1 Jul 2026 | Interactive Drug Benefit List observed 2026-09-17; record coverage update 2026-07-01 | A-C22 R21-C536 R21-C537 R21-C538 R21-C539 R21-C540 |
| Saskatchewan | moderate | Exception Drug Status (diabetes) for the four generics and Ozempic; criteria: T2D after metformin plus sulfonylurea | No weight product found other than Imcivree | Imcivree EDS for BBS obesity age 6 and up under specialist care | Four generics grouped with the matching Ozempic DIN, I/C = Y | Formulary Appendix A accessed 2026-09-17; document date not extracted | A-C23 R21-C541 R21-C542 |
| Manitoba | moderate | EDS (diabetes) for seven injectable semaglutide DINs; criteria: T2D after metformin plus sulfonylurea. Ozempic excluded from the no-cost MEPP list, which is a separate programme | No weight product found other than Imcivree | Imcivree EDS for BBS obesity age 6 and up; specialist criteria; initial six-month approval | Four generics grouped with matching Ozempic DINs, 150th edition, effective 1 Sep 2026 | Formulary effective 2026-09-01 | A-C24 R21-C543 R21-C544 R21-C545 |
| Ontario | full | Limited Use (diabetes) codes 665, 666, 667 for injectables and 662, 663, 664, 738, 739, 740 for Rybelsus (all strengths including new 1.5, 4, 9 mg); generic drug benefit price 78.1410 versus Ozempic 227.9400, Ministry pays 78.1410 either way; Rybelsus 7.5303 per tablet | Sevmia and Wegovy form an Off-Formulary Interchangeable group; Sevmia price 325.0480, Ministry pays nothing. No funded chronic weight management benefit. Xenical on EAP with diabetes-based criteria | Imcivree on the EAP reimbursable-product list, drug benefit price 4022.9046 per vial, effective 2025-10-10; criteria not found in the Jan 2025 Frequently Requested Drugs PDF | Three groups: Apo 02568020 with Ozempic 02540258; Dr. Reddy's 02567806 with Ozempic 02471477; Apo 02568012, Dr. Reddy's 02567814 and Ozempic 02471469 together. Rybelsus strengths not interchangeable | Formulary edition v2.17, effective 2026-08-31, last updated 2026-09-02 | A-C20 R21-C496 R21-C497 R21-C498 R21-C499 R21-C500 R21-C501 R21-C502 R21-C503 R21-C504 R21-C505 R21-C506 R21-C507 R21-C508 R21-C509 R21-C510 R21-C511 R21-C512 R21-C513 R21-C514 R21-C515 R21-C516 R21-C517 R21-C518 R21-C519 R21-C520 R21-C521 R21-C522 R21-C523 R21-C524 R21-C525 R21-C526 R21-C527 R21-C558 R21-C559 R21-C560 R21-C561 R21-C562 |
| Quebec | moderate | Médicament d'exception (diabetes) for Ozempic, Rybelsus and the four generic DINs; criterion: T2D with metformin where sulfonylurea is contraindicated, not tolerated or ineffective; injected reimbursement ceiling 1 mg weekly | Wegovy, Saxenda, Zepbound and Sevmia returned no result in the RAMQ covered-drug search on 2026-09-17. Earlier pass noted an April 2026 RAMQ decision declining Wegovy and an INESSS pilot recommendation; confirm in R3-1 | Imcivree not found in RAMQ search | unknown: legal list has separate semaglutide and semaglutide (generic) headings; cross-brand interchangeability not established. R3-1 to close | Liste des médicaments effective 2026-08-27; live search 2026-09-17 | A-C25 R21-C546 R21-C547 R21-C548 R21-C549 R21-C567 R21-C568 R21-C569 R21-C570 R21-C571 |
| New Brunswick | moderate | Special Authorization (diabetes) for Ozempic 2 mg/1.5 mL, 2 mg/3 mL, 4 mg/3 mL; criteria: adult T2D added to metformin, HbA1c 7 percent or more, metformin details; maximum one autoinjector every 4 weeks | No weight product found. Liraglutide, Victoza and Saxenda not found in the 136-page criteria PDF | not found in sources checked | generic DINs not enumerated in the SA criteria PDF; formulary search still to do (R3-1) | SA criteria PDF dated 2026-09-10 | A-C26 R21-C528 R21-C529 R21-C530 R21-C531 |
| Nova Scotia | moderate | Exception Status (diabetes) for Ozempic and generics after metformin plus sulfonylurea; maximum one pen every 4 weeks; Rybelsus also restricted | No weight product found other than Imcivree | Imcivree exception criteria for BBS obesity | Four generics grouped with matching Ozempic DINs, all interchangeable | Formulary and criteria September 2026 | A-C27 R21-C550 R21-C551 |
| Prince Edward Island | moderate | Special Authorization (diabetes) for the four generics and Ozempic, program codes DNQW; criteria say Ozempic and generics; quantity one pen per four weeks | No weight product found other than Imcivree | Imcivree SA, program codes MNQW, for BBS obesity age 6 and up | unknown: PEI formulary states it must not be used to determine interchangeability. R3-1 to close | Formulary August 2026; SA form dated Nov 2024 | A-C28 R21-C552 R21-C553 R21-C554 R21-C555 |
| Newfoundland and Labrador | moderate | Special Authorization (diabetes) for Ozempic and generics; criteria: T2D with metformin after inadequate control, or documented metformin intolerance; 1 mg weekly ceiling | No weight product found | not found in sources checked | criteria say Ozempic and generics; DINs not enumerated | Criteria PDF updated 2026-08-12 (Ozempic section July 2026, Rybelsus section May 2026) | A-C29 R21-C532 R21-C533 R21-C534 R21-C535 |
| Yukon | programme-level only | Yukon national pharmacare programme (no-cost list) excludes GLP-1 agents including Ozempic; other Yukon Pharmacare and Chronic Disease programmes may apply, product rules not extracted | not researched | not researched | not researched | Programme page current 2026 (accessed 2026-09-16) | A-C30 |
| Northwest Territories | programme-level only | NWT Pharmacare formulary effective 1 Aug 2026 uses the NIHB list with exclusions and lists Ozempic as a limited diabetes benefit with a metformin prerequisite; generics and other products not extracted | not researched | not researched | not researched (territorial interchangeable list is separate from plan coverage) | Formulary effective 2026-08-01 | A-C30 |
| Nunavut | programme-level only | Extended Health Benefits and NIHB are separate routes; no product-level list extracted | not researched | not researched | not researched | EHB page accessed 2026-09-16 | A-C30 |
What the record shows as of the document dates
- In every province reviewed, injectable semaglutide (Ozempic and the generics) is listed for type 2 diabetes under special authorization, exception status, limited use or an equivalent, with metformin-based criteria. The ceiling in several provinces is 1 mg weekly or one pen per four weeks.
- No province reviewed lists Wegovy, Saxenda, Zepbound, Rybelsus or Sevmia for chronic weight management on the public plan. British Columbia's Wegovy decision is Non-benefit, dated 18 December 2025, after the pan-Canadian negotiation ended without agreement; the Ministry said it will review generic semaglutide submissions when marketed. Ontario places Sevmia and Wegovy in an off-formulary interchangeable group, with the Ministry paying nothing.
- Imcivree is listed for obesity due to Bardet-Biedl syndrome in the provinces that were checked at that depth, with specialist criteria and age 6 and up.
- Interchangeability of the generics with Ozempic is documented for Alberta, Saskatchewan, Manitoba, Ontario and Nova Scotia; it is unknown for Quebec and Prince Edward Island; New Brunswick and Newfoundland and Labrador say "Ozempic and generics" without listing DINs.
- The three territories have programme-level facts only. Yukon's no-cost national pharmacare list excludes GLP-1 agents; the NWT formulary lists Ozempic as a limited diabetes benefit; Nunavut's Extended Health Benefits and the federal Non-Insured Health Benefits program are separate routes that this record has not mapped at product level.
Unknown states used on this site
Company self-report: offered The company's own page says it offers the service there. This is not a check of licensing or quality.
Conflicting Two or more of the company's own pages disagree. Both values are shown with their dates.
Not found in sources checked The researcher looked and did not find it. This is not the same as not offered.
Explicitly not offered The company's page says it does not serve that place.
Not applicable The service is a public program limited to one province by design.
Not researched Nobody has looked yet.
Open gaps that affect coverage claims
This table scrolls sideways.
| Gap | Topic | State | What it blocks | Resolution step | Priority | Status after round 2 |
|---|---|---|---|---|---|---|
| G03 | Factual extraction gap: province × product/DIN × indication × plan benefits and interchangeability | not researched | Whether a national coverage checker can return an accurate benefit result | Complete only pilot jurisdictions first; join current criteria, plan eligibility, DIN, substitution policy, effective date and payment basis; retain all others as unverified | P0 before coverage claims | PARTLY CLOSED by R2-1 for BC and Ontario (benefit status, SA/LU criteria, interchangeability groups). Other provinces: generics listed; QC and PEI interchangeability still unknown. Territories not researched. |
| G04 | Factual access gap: BC current decision/SA documents and New Brunswick current criteria | source inaccessible | BC pilot coverage facts and any NB benefit statements | Reopen official documents and check for superseding decisions; do not substitute historical bulletins or indexed snippets for completed current criteria audit | P0 before affected coverage claims | CLOSED by R2-1: BC Wegovy decision PDF opened (Non-benefit, 2025-12-18); NB SA criteria PDF dated 2026-09-10 recovered. |
| G05 | Factual extraction gap: territorial/NIHB eligibility and product benefits | not researched | Territorial expansion and avoiding blanket coverage assumptions | Extract each applicable plan separately, including DIN and indication criteria; verify alternative service and dispensing routes before territorial expansion | P1 expansion gate | OPEN: territories and NIHB not researched in Round 2 (by design). |
Sources for this page
Every claim ID below is a row in the evidence ledger. The source date is the date the source itself carries; the access date is when the researcher opened it. A claim with several rows is one claim with several sources, not several confirmations.
This table scrolls sideways.
| Claim | What the source says | Source | Source date | Accessed | Label |
|---|---|---|---|---|---|
| A-C21 source 1 of 2 | Latest located BC Wegovy/CVD decision says Non-benefit; pCPA negotiation ended without agreement | www2.gov.bc.ca/assets/gov/health/health-drug-coverage/pha... | 2025-12-18 | 2026-09-16 | directly observed |
| A-C21 source 2 of 2 | Current BC SA drug list includes semaglutide/Ozempic; diabetes form revised February 2026 | www2.gov.bc.ca//gov/content/health/practitioner-professio... | List 2026-05-06; form 2026-02-13 | 2026-09-16 | directly observed |
| R21-C466 | Wegovy decision is Non-benefit, dated December 18 2025. Reviewed use is chronic weight management adjunct to reduced-calorie diet/increased activity in adults BMI at least 27 with established CVD (MI, prior stroke or PAD). | www2.gov.bc.ca/assets/gov/health/health-drug-coverage/pha... | decision 2025-12-18 | 2026-09-17 | regulator-confirmed |
| R21-C467 | No later semaglutide or any tirzepatide decision was found in the current BC decision listing. Semaglutide entries are Ozempic 2020-12-15, Rybelsus 2023-01-31 and Wegovy 2025-12-18. | www2.gov.bc.ca/gov/content/health/health-drug-coverage/ph... | updated 2026-09-16 | 2026-09-17 | directly observed |
| R21-C468 | BC provides exceptional Imcivree reimbursement through its EDRD pathway for BBS-related obesity in adults and children aged six and older; decision July 29, 2025. | www2.gov.bc.ca/assets/gov/health/health-drug-coverage/pha... | decision 2025-07-29 | 2026-09-17 | regulator-confirmed |
| R21-C469 | BC formulary DIN 02471469 Ozempic, displayed presentation 1/0.75 (3) PEN INJCTR: plan SA, Available With Special Authority Only; SA needed Yes; RDP No; displayed listing date 15-Dec-2020; max days supply/fill 100. | pharmacareformularysearch.gov.bc.ca/Search.xhtml | coverage data 2026-09-08 | 2026-09-17 | regulator-confirmed |
| R21-C470 | BC formulary DIN 02540258 Ozempic, displayed presentation .25 OR 0.5 PEN INJCTR: plan SA, Available With Special Authority Only; SA needed Yes; RDP No; displayed listing date 06-Feb-2024; max days supply/fill 100. | pharmacareformularysearch.gov.bc.ca/Search.xhtml | coverage data 2026-09-08 | 2026-09-17 | regulator-confirmed |
| R21-C471 | BC formulary DIN 02567806 Semaglutide Injection (Dr. Reddy’s), displayed presentation 0.25 OR .5 PEN INJCTR: plan SA, Available With Special Authority Only; SA needed Yes; RDP No; displayed listing date 15-Jun-2026; max days supply/fill 100. | pharmacareformularysearch.gov.bc.ca/Search.xhtml | coverage data 2026-09-08 | 2026-09-17 | regulator-confirmed |
| R21-C472 | BC formulary DIN 02567814 Semaglutide Injection (Dr. Reddy’s), displayed presentation 1/0.75 (3) PEN INJCTR: plan SA, Available With Special Authority Only; SA needed Yes; RDP No; displayed listing date 15-Jun-2026; max days supply/fill 100. | pharmacareformularysearch.gov.bc.ca/Search.xhtml | coverage data 2026-09-08 | 2026-09-17 | regulator-confirmed |
| R21-C473 | BC formulary DIN 02568012 Apo-Semaglutide Injection, displayed presentation 1/0.75 (3) PEN INJCTR: plan SA, Available With Special Authority Only; SA needed Yes; RDP No; displayed listing date 15-Jun-2026; max days supply/fill 100. | pharmacareformularysearch.gov.bc.ca/Search.xhtml | coverage data 2026-09-08 | 2026-09-17 | regulator-confirmed |
| R21-C474 | BC formulary DIN 02568020 Apo-Semaglutide Injection, displayed presentation .25 OR 0.5 PEN INJCTR: plan SA, Available With Special Authority Only; SA needed Yes; RDP No; displayed listing date 15-Jun-2026; max days supply/fill 100. | pharmacareformularysearch.gov.bc.ca/Search.xhtml | coverage data 2026-09-08 | 2026-09-17 | regulator-confirmed |
| R21-C475 | BC formulary DIN 02497581 Rybelsus, displayed presentation 3 MG TABLET: plan NB, Non-Benefit; SA needed No; RDP No; displayed listing date 01-Jan-1994; max days supply/fill 0. | pharmacareformularysearch.gov.bc.ca/Search.xhtml | coverage data 2026-09-08 | 2026-09-17 | regulator-confirmed |
| R21-C476 | BC formulary DIN 02497603 Rybelsus, displayed presentation 7 MG TABLET: plan NB, Non-Benefit; SA needed No; RDP No; displayed listing date 01-Jan-1994; max days supply/fill 0. | pharmacareformularysearch.gov.bc.ca/Search.xhtml | coverage data 2026-09-08 | 2026-09-17 | regulator-confirmed |
| R21-C477 | BC formulary DIN 02497611 Rybelsus, displayed presentation 14 MG TABLET: plan NB, Non-Benefit; SA needed No; RDP No; displayed listing date 01-Jan-1994; max days supply/fill 0. | pharmacareformularysearch.gov.bc.ca/Search.xhtml | coverage data 2026-09-08 | 2026-09-17 | regulator-confirmed |
| R21-C478 | BC formulary DIN 02522551 Wegovy, displayed presentation .25MG/.5 PEN INJCTR: plan NB, Non-Benefit; SA needed No; RDP No; displayed listing date 01-Jan-1994; max days supply/fill 0. | pharmacareformularysearch.gov.bc.ca/Search.xhtml | coverage data 2026-09-08 | 2026-09-17 | regulator-confirmed |
| R21-C479 | BC formulary DIN 02522578 Wegovy, displayed presentation .5MG/.5ML PEN INJCTR: plan NB, Non-Benefit; SA needed No; RDP No; displayed listing date 01-Jan-1994; max days supply/fill 0. | pharmacareformularysearch.gov.bc.ca/Search.xhtml | coverage data 2026-09-08 | 2026-09-17 | regulator-confirmed |
| R21-C480 | BC formulary DIN 02522586 Wegovy, displayed presentation 1MG/.5ML PEN INJCTR: plan NB, Non-Benefit; SA needed No; RDP No; displayed listing date 01-Jan-1994; max days supply/fill 0. | pharmacareformularysearch.gov.bc.ca/Search.xhtml | coverage data 2026-09-08 | 2026-09-17 | regulator-confirmed |
| R21-C481 | BC formulary DIN 02522594 Wegovy, displayed presentation 1.7MG/.75 PEN INJCTR: plan NB, Non-Benefit; SA needed No; RDP No; displayed listing date 01-Jan-1994; max days supply/fill 0. | pharmacareformularysearch.gov.bc.ca/Search.xhtml | coverage data 2026-09-08 | 2026-09-17 | regulator-confirmed |
| R21-C482 | BC formulary DIN 02522608 Wegovy, displayed presentation 2.4MG/.75 PEN INJCTR: plan NB, Non-Benefit; SA needed No; RDP No; displayed listing date 01-Jan-1994; max days supply/fill 0. | pharmacareformularysearch.gov.bc.ca/Search.xhtml | coverage data 2026-09-08 | 2026-09-17 | regulator-confirmed |
| R21-C483 | BC formulary DIN 02528509 Wegovy, displayed presentation .25MG/.37 PEN INJCTR: plan NB, Non-Benefit; SA needed No; RDP No; displayed listing date 01-Jan-1994; max days supply/fill 0. | pharmacareformularysearch.gov.bc.ca/Search.xhtml | coverage data 2026-09-08 | 2026-09-17 | regulator-confirmed |
| R21-C484 | BC formulary DIN 02528517 Wegovy, displayed presentation .5MG/.37 PEN INJCTR: plan NB, Non-Benefit; SA needed No; RDP No; displayed listing date 01-Jan-1994; max days supply/fill 0. | pharmacareformularysearch.gov.bc.ca/Search.xhtml | coverage data 2026-09-08 | 2026-09-17 | regulator-confirmed |
| R21-C485 | BC formulary DIN 02528525 Wegovy, displayed presentation 1/.75 (3) PEN INJCTR: plan NB, Non-Benefit; SA needed No; RDP No; displayed listing date 01-Jan-1994; max days supply/fill 0. | pharmacareformularysearch.gov.bc.ca/Search.xhtml | coverage data 2026-09-08 | 2026-09-17 | regulator-confirmed |
| R21-C486 | BC formulary DIN 02528533 Wegovy, displayed presentation 1.7/.75(3) PEN INJCTR: plan NB, Non-Benefit; SA needed No; RDP No; displayed listing date 01-Jan-1994; max days supply/fill 0. | pharmacareformularysearch.gov.bc.ca/Search.xhtml | coverage data 2026-09-08 | 2026-09-17 | regulator-confirmed |
| R21-C487 | BC formulary DIN 02528541 Wegovy, displayed presentation 2.4/.75(3) PEN INJCTR: plan NB, Non-Benefit; SA needed No; RDP No; displayed listing date 01-Jan-1994; max days supply/fill 0. | pharmacareformularysearch.gov.bc.ca/Search.xhtml | coverage data 2026-09-08 | 2026-09-17 | regulator-confirmed |
| R21-C488 | BC formulary DIN 02351064 Victoza, displayed presentation 0.6 MG/0.1 PEN INJCTR: plan NB, Non-Benefit; SA needed No; RDP No; displayed listing date 01-Jan-1994; max days supply/fill 0. | pharmacareformularysearch.gov.bc.ca/Search.xhtml | coverage data 2026-09-08 | 2026-09-17 | regulator-confirmed |
| R21-C489 | BC formulary DIN 02437899 Saxenda, displayed presentation 3 MG/0.5ML PEN INJCTR: plan NB, Non-Benefit; SA needed No; RDP No; displayed listing date 01-Jan-1994; max days supply/fill 0. | pharmacareformularysearch.gov.bc.ca/Search.xhtml | coverage data 2026-09-08 | 2026-09-17 | regulator-confirmed |
| R21-C490 | BC tirzepatide All Benefits search returned no drugs found; no tirzepatide DIN could be extracted. | pharmacareformularysearch.gov.bc.ca/Search.xhtml | coverage data 2026-09-08 | 2026-09-17 | directly observed |
| R21-C491 | Rybelsus 1.5 mg, 4 mg and 9 mg were not found among the 19 BC semaglutide search results. | pharmacareformularysearch.gov.bc.ca/Search.xhtml | coverage data 2026-09-08 | 2026-09-17 | unknown |
| R21-C492 | Current BC SA drug list includes semaglutide (Ozempic) and says listed drugs are covered by Fair PharmaCare and Plans W, C and B once SA is approved. | www2.gov.bc.ca/gov/content/health/practitioner-profession... | updated 2026-08-05 | 2026-09-17 | regulator-confirmed |
| R21-C493 | BC semaglutide SA criteria cover type 2 diabetes after inadequate glycemic control on maximally tolerated metformin; approval indefinite, no practitioner exemptions. | www2.gov.bc.ca/gov/content/health/practitioner-profession... | updated 2026-04-21 | 2026-09-17 | regulator-confirmed |
| R21-C494 | BC semaglutide coverage is limited to 1 mg weekly using the intended 1 mg delivery device; 2 mg was under reimbursement review; two 0.5 mg injections using the lower-dose device are not covered. Concurrent DPP-4 inhibitor coverage is not provided. | www2.gov.bc.ca/gov/content/health/practitioner-profession... | updated 2026-04-21 | 2026-09-17 | regulator-confirmed |
| R21-C495 | BC current semaglutide SA form is HLTH 5826 Rev. 2026/02/13; it is for diabetes and has Prescriber Information, Patient Information, Medication Requested and Criteria for Indefinite Coverage sections. | www2.gov.bc.ca/assets/gov/health/forms/5826fil.pdf | HLTH 5826 Rev. 2026/02/13 | 2026-09-17 | regulator-confirmed |
| A-C22 | Alberta semaglutide results show step therapy/special authorization | idbl.ab.bluecross.ca/idbl/drugsList?searchTerm=semaglutide | Live record observed 2026-09-16 | 2026-09-16 | directly observed |
| R21-C536 | Alberta semaglutide results list Apo02568012 and02568020 and DrReddy02567806 and02567814 under step therapy/special authorization; Aspen02570912 and02570920 appear under review, not as benefits. | idbl.ab.bluecross.ca/idbl/drugsList?searchTerm=semaglutide | Last Updated field blank in opened web and browser views | 2026-09-17 | regulator-confirmed |
| R21-C537 | Alberta Apo02568012 and DrReddy02567814 are grouped interchangeable with Ozempic02471469. Apo record coverage update July1 2026. | idbl.ab.bluecross.ca/idbl/drugDetails?_cid=f2600d39-e77b-... | listed/coverage update 2026-07-01 | 2026-09-17 | regulator-confirmed |
| R21-C538 | Alberta DrReddy02567806 is grouped interchangeable with Ozempic02471477; record coverage update July1 2026. | idbl.ab.bluecross.ca/idbl/drugDetails?_cid=95a9eb0c-4dae-... | listed/coverage update 2026-07-01 | 2026-09-17 | regulator-confirmed |
| R21-C539 | Alberta Apo02568020 has Interchangeable Products No; Ozempic02540258 is under review and also No in the result table. | idbl.ab.bluecross.ca/idbl/drugsList?searchTerm=semaglutide | Last Updated field blank in opened web and browser views | 2026-09-17 | regulator-confirmed |
| R21-C540 | Alberta Imcivree DIN02537745 has Special Authorization coverage for weight management in patients6years or older with clinically/genetically confirmed BBS and obesity; coverage update September1 2025. | idbl.ab.bluecross.ca/idbl/drugDetails?_cid=7391a720-917a-... | listed/coverage update 2025-09-01 | 2026-09-17 | regulator-confirmed |
| A-C23 | Saskatchewan appendix lists restricted T2D semaglutide criteria | formulary.drugplan.ehealthsask.ca/PDFs/APPENDIXA.pdf | Current posted document; exact effective date not extracted | 2026-09-16 | directly observed |
| R21-C541 | Saskatchewan lists Apo02568020 with Ozempic02540258; DrReddy02567806 with Ozempic02471477; Apo02568012 and DrReddy02567814 with Ozempic02471469. Each is EDS and I/C=Y, where I/C means Interchangeable. | formulary.drugplan.ehealthsask.ca/ | effective 2026-09-01; updated 2026-08-27 | 2026-09-17 | regulator-confirmed |
| R21-C542 | Saskatchewan exception criteria list Imcivree10mg/mL for weight management in adults and children6years or older with clinical/genetic BBS under specialist care. | formulary.drugplan.ehealthsask.ca/PDFs/APPENDIXA.pdf | date not shown in extracted document; no 2026 text found | 2026-09-17 | regulator-confirmed |
| A-C24 source 1 of 2 | Manitoba current formulary/EDS portal effective September 1 | gov.mb.ca/health/mdbif/ | 2026-09-01 | 2026-09-16 | directly observed |
| A-C24 source 2 of 2 | Ozempic excluded from MEPP does not establish exclusion from all Manitoba programmes | gov.mb.ca/health/pharmacare/mepp.html | Current 2026 page | 2026-09-16 | directly observed |
| R21-C543 | Manitoba Sept1 2026 interchangeability formulary lists Apo02568020 with Ozempic02540258; Apo02568012 and DrReddy02567814 with Ozempic02471469; DrReddy02567806 with Ozempic02471477. | gov.mb.ca/health/mdbif/docs/manitoba-drug-interchangeabil... | 150th edition effective 2026-09-01 | 2026-09-17 | regulator-confirmed |
| R21-C544 | Manitoba EDS lists the seven generic/originator injectable semaglutide DINs for T2DM after inadequate control with metformin plus sulfonylurea. | gov.mb.ca/health/mdbif/docs/edsnotice.pdf | 2026-09-01 | 2026-09-17 | regulator-confirmed |
| R21-C545 | Manitoba EDS lists Imcivree02537745 for weight management in adult/pediatric patients6years and older with obesity due to BBS; specialist criteria and initial six-month approval. | gov.mb.ca/health/mdbif/docs/edsnotice.pdf | 2026-09-01 | 2026-09-17 | regulator-confirmed |
| A-C20 | Ontario generic semaglutide entries show interchangeable/Limited Use and 78.1410 CAD unit benefit price | formulary.health.gov.on.ca/formulary/results.xhtml?q=sema... | Live record observed 2026-09-16 | 2026-09-16 | directly observed |
| R21-C496 | Ontario DIN 02568020 Apo-Semaglutide Injection 0.68 mg/mL, 3 mL pen pack: Limited Use 667; DBP or Unit Price 78.1410 CAD; MOH pays 78.1410; interchangeability Yes. | formulary.health.gov.on.ca/formulary/results.xhtml?q=sema... | edition effective 2026-08-31; last updated 02/09/2026; version 2.17 | 2026-09-17 | regulator-confirmed |
| R21-C497 | Ontario DIN 02540258 Ozempic 0.68 mg/mL, 3 mL pen pack: Limited Use 667; DBP or Unit Price 227.9400 CAD; MOH pays 78.1410; interchangeability Yes. | formulary.health.gov.on.ca/formulary/results.xhtml?q=sema... | edition effective 2026-08-31; last updated 02/09/2026; version 2.17 | 2026-09-17 | regulator-confirmed |
| R21-C498 | Ontario DIN 02471477 Ozempic 1.34 mg/mL, 1.5 mL pen pack: Limited Use 666; DBP or Unit Price 227.9400 CAD; MOH pays 78.1410; interchangeability Yes. | formulary.health.gov.on.ca/formulary/results.xhtml?q=sema... | edition effective 2026-08-31; last updated 02/09/2026; version 2.17 | 2026-09-17 | regulator-confirmed |
| R21-C499 | Ontario DIN 02567806 Semaglutide Injection (Dr. Reddy’s) 1.34 mg/mL, 1.5 mL pen pack: Limited Use 666; DBP or Unit Price 78.1410 CAD; MOH pays 78.1410; interchangeability Yes. | formulary.health.gov.on.ca/formulary/results.xhtml?q=sema... | edition effective 2026-08-31; last updated 02/09/2026; version 2.17 | 2026-09-17 | regulator-confirmed |
| R21-C500 | Ontario DIN 02568012 Apo-Semaglutide Injection 1.34 mg/mL, 3 mL pen pack: Limited Use 665; DBP or Unit Price 78.1410 CAD; MOH pays 78.1410; interchangeability Yes. | formulary.health.gov.on.ca/formulary/results.xhtml?q=sema... | edition effective 2026-08-31; last updated 02/09/2026; version 2.17 | 2026-09-17 | regulator-confirmed |
| R21-C501 | Ontario DIN 02471469 Ozempic 1.34 mg/mL, 3 mL pen pack: Limited Use 665; DBP or Unit Price 227.9400 CAD; MOH pays 78.1410; interchangeability Yes. | formulary.health.gov.on.ca/formulary/results.xhtml?q=sema... | edition effective 2026-08-31; last updated 02/09/2026; version 2.17 | 2026-09-17 | regulator-confirmed |
| R21-C502 | Ontario DIN 02567814 Semaglutide Injection (Dr. Reddy’s) 1.34 mg/mL, 3 mL pen pack: Limited Use 665; DBP or Unit Price 78.1410 CAD; MOH pays 78.1410; interchangeability Yes. | formulary.health.gov.on.ca/formulary/results.xhtml?q=sema... | edition effective 2026-08-31; last updated 02/09/2026; version 2.17 | 2026-09-17 | regulator-confirmed |
| R21-C503 | Ontario DIN 02569582 Sevmia 4 mg/3 mL pen: Off-Formulary Interchangeable; LU No; not General Benefit; DBP or Unit Price 325.0480 CAD; MOH pays N/A; interchangeability Yes. | formulary.health.gov.on.ca/formulary/results.xhtml?q=sema... | edition effective 2026-08-31; last updated 02/09/2026; version 2.17 | 2026-09-17 | regulator-confirmed |
| R21-C504 | Ontario DIN 02528525 Wegovy 4 mg/3 mL pen: Off-Formulary Interchangeable; LU No; not General Benefit; DBP or Unit Price N/A CAD; MOH pays N/A; interchangeability Yes. | formulary.health.gov.on.ca/formulary/results.xhtml?q=sema... | edition effective 2026-08-31; last updated 02/09/2026; version 2.17 | 2026-09-17 | regulator-confirmed |
| R21-C505 | Ontario DIN 02551012 Rybelsus 1.5 mg tablet: Limited Use 738; DBP or Unit Price 7.5303 CAD; MOH pays 7.5303; interchangeability No. | formulary.health.gov.on.ca/formulary/results.xhtml?q=sema... | edition effective 2026-08-31; last updated 02/09/2026; version 2.17 | 2026-09-17 | regulator-confirmed |
| R21-C506 | Ontario DIN 02497581 Rybelsus 3 mg tablet: Limited Use 662; DBP or Unit Price 7.5303 CAD; MOH pays 7.5303; interchangeability No. | formulary.health.gov.on.ca/formulary/results.xhtml?q=sema... | edition effective 2026-08-31; last updated 02/09/2026; version 2.17 | 2026-09-17 | regulator-confirmed |
| R21-C507 | Ontario DIN 02551020 Rybelsus 4 mg tablet: Limited Use 739; DBP or Unit Price 7.5303 CAD; MOH pays 7.5303; interchangeability No. | formulary.health.gov.on.ca/formulary/results.xhtml?q=sema... | edition effective 2026-08-31; last updated 02/09/2026; version 2.17 | 2026-09-17 | regulator-confirmed |
| R21-C508 | Ontario DIN 02497603 Rybelsus 7 mg tablet: Limited Use 663; DBP or Unit Price 7.5303 CAD; MOH pays 7.5303; interchangeability No. | formulary.health.gov.on.ca/formulary/results.xhtml?q=sema... | edition effective 2026-08-31; last updated 02/09/2026; version 2.17 | 2026-09-17 | regulator-confirmed |
| R21-C509 | Ontario DIN 02551039 Rybelsus 9 mg tablet: Limited Use 740; DBP or Unit Price 7.5303 CAD; MOH pays 7.5303; interchangeability No. | formulary.health.gov.on.ca/formulary/results.xhtml?q=sema... | edition effective 2026-08-31; last updated 02/09/2026; version 2.17 | 2026-09-17 | regulator-confirmed |
| R21-C510 | Ontario DIN 02497611 Rybelsus 14 mg tablet: Limited Use 664; DBP or Unit Price 7.5303 CAD; MOH pays 7.5303; interchangeability No. | formulary.health.gov.on.ca/formulary/results.xhtml?q=sema... | edition effective 2026-08-31; last updated 02/09/2026; version 2.17 | 2026-09-17 | regulator-confirmed |
| R21-C511 | Ontario interchangeable grouping A (report label) contains 02568020 Apo-Semaglutide + 02540258 Ozempic. | formulary.health.gov.on.ca/formulary/interchangeable.xhtm... | last updated 02/09/2026; version 2.17 | 2026-09-17 | regulator-confirmed |
| R21-C512 | Ontario interchangeable grouping B (report label) contains 02567806 Dr. Reddy’s + 02471477 Ozempic. | formulary.health.gov.on.ca/formulary/interchangeable.xhtm... | last updated 02/09/2026; version 2.17 | 2026-09-17 | regulator-confirmed |
| R21-C513 | Ontario interchangeable grouping C (report label) contains 02568012 Apo-Semaglutide + 02567814 Dr. Reddy’s + 02471469 Ozempic. | formulary.health.gov.on.ca/formulary/interchangeable.xhtm... | last updated 02/09/2026; version 2.17 | 2026-09-17 | regulator-confirmed |
| R21-C514 | Ontario interchangeable grouping D (report label) contains 02569582 Sevmia + 02528525 Wegovy. | formulary.health.gov.on.ca/formulary/interchangeable.xhtm... | last updated 02/09/2026; version 2.17 | 2026-09-17 | regulator-confirmed |
| R21-C515 | Ontario LU 667, 0.68 mg/mL 3 mL pen: Adults with T2DM inadequately controlled on maximally tolerated metformin, or metformin contraindicated/inappropriate. No funding with another GLP-1 RA or DPP-4 inhibitor; no concurrent oral and injectable semaglutide; one dosage format only. Authorization indefinite. Maximum reimbursed dose: As specified in product monograph. | formulary.health.gov.on.ca/formulary/limitedUseNotes.xhtm... | last updated 02/09/2026; version 2.17 | 2026-09-17 | regulator-confirmed |
| R21-C516 | Ontario LU 666, 1.34 mg/mL 1.5 mL pen: Adults with T2DM inadequately controlled on maximally tolerated metformin, or metformin contraindicated/inappropriate. No funding with another GLP-1 RA or DPP-4 inhibitor; no concurrent oral and injectable semaglutide; one dosage format only. Authorization indefinite. Maximum reimbursed dose: As specified in product monograph. | formulary.health.gov.on.ca/formulary/limitedUseNotes.xhtm... | last updated 02/09/2026; version 2.17 | 2026-09-17 | regulator-confirmed |
| R21-C517 | Ontario LU 665, 1.34 mg/mL 3 mL pen: Adults with T2DM inadequately controlled on maximally tolerated metformin, or metformin contraindicated/inappropriate. No funding with another GLP-1 RA or DPP-4 inhibitor; no concurrent oral and injectable semaglutide; one dosage format only. Authorization indefinite. Maximum reimbursed dose: As specified in product monograph. | formulary.health.gov.on.ca/formulary/limitedUseNotes.xhtm... | last updated 02/09/2026; version 2.17 | 2026-09-17 | regulator-confirmed |
| R21-C518 | Ontario LU 738, 1.5 mg tablet: Adults with T2DM inadequately controlled on maximally tolerated metformin, or metformin contraindicated/inappropriate. No funding with another GLP-1 RA or DPP-4 inhibitor; no concurrent oral and injectable semaglutide; one dosage format only. Authorization indefinite. Maximum reimbursed dose: 1.5 mg once daily. | formulary.health.gov.on.ca/formulary/limitedUseNotes.xhtm... | last updated 02/09/2026; version 2.17 | 2026-09-17 | regulator-confirmed |
| R21-C519 | Ontario LU 662, 3 mg tablet: Adults with T2DM inadequately controlled on maximally tolerated metformin, or metformin contraindicated/inappropriate. No funding with another GLP-1 RA or DPP-4 inhibitor; no concurrent oral and injectable semaglutide; one dosage format only. Authorization indefinite. Maximum reimbursed dose: 3 mg once daily. | formulary.health.gov.on.ca/formulary/limitedUseNotes.xhtm... | last updated 02/09/2026; version 2.17 | 2026-09-17 | regulator-confirmed |
| R21-C520 | Ontario LU 739, 4 mg tablet: Adults with T2DM inadequately controlled on maximally tolerated metformin, or metformin contraindicated/inappropriate. No funding with another GLP-1 RA or DPP-4 inhibitor; no concurrent oral and injectable semaglutide; one dosage format only. Authorization indefinite. Maximum reimbursed dose: 4 mg once daily. | formulary.health.gov.on.ca/formulary/limitedUseNotes.xhtm... | last updated 02/09/2026; version 2.17 | 2026-09-17 | regulator-confirmed |
| R21-C521 | Ontario LU 663, 7 mg tablet: Adults with T2DM inadequately controlled on maximally tolerated metformin, or metformin contraindicated/inappropriate. No funding with another GLP-1 RA or DPP-4 inhibitor; no concurrent oral and injectable semaglutide; one dosage format only. Authorization indefinite. Maximum reimbursed dose: 7 mg once daily. | formulary.health.gov.on.ca/formulary/limitedUseNotes.xhtm... | last updated 02/09/2026; version 2.17 | 2026-09-17 | regulator-confirmed |
| R21-C522 | Ontario LU 740, 9 mg tablet: Adults with T2DM inadequately controlled on maximally tolerated metformin, or metformin contraindicated/inappropriate. No funding with another GLP-1 RA or DPP-4 inhibitor; no concurrent oral and injectable semaglutide; one dosage format only. Authorization indefinite. Maximum reimbursed dose: 9 mg once daily. | formulary.health.gov.on.ca/formulary/limitedUseNotes.xhtm... | last updated 02/09/2026; version 2.17 | 2026-09-17 | regulator-confirmed |
| R21-C523 | Ontario LU 664, 14 mg tablet: Adults with T2DM inadequately controlled on maximally tolerated metformin, or metformin contraindicated/inappropriate. No funding with another GLP-1 RA or DPP-4 inhibitor; no concurrent oral and injectable semaglutide; one dosage format only. Authorization indefinite. Maximum reimbursed dose: 14 mg once daily. | formulary.health.gov.on.ca/formulary/limitedUseNotes.xhtm... | last updated 02/09/2026; version 2.17 | 2026-09-17 | regulator-confirmed |
| R21-C524 | Ontario tirzepatide search displayed no product records in the browser result page. | formulary.health.gov.on.ca/formulary/results.xhtml?q=tirz... | edition effective 2026-08-31; last updated 02/09/2026; version 2.17 | 2026-09-17 | directly observed |
| R21-C525 | Ontario liraglutide search displayed no product records in the browser result page. | formulary.health.gov.on.ca/formulary/results.xhtml?q=lira... | edition effective 2026-08-31; last updated 02/09/2026; version 2.17 | 2026-09-17 | directly observed |
| R21-C526 | All three new Rybelsus strengths appear in Ontario: 02551012 1.5 mg LU738, 02551020 4 mg LU739, 02551039 9 mg LU740; each DBP and MOH amount 7.5303 per tablet and not interchangeable in result table. | formulary.health.gov.on.ca/formulary/results.xhtml?q=sema... | edition effective 2026-08-31; last updated 02/09/2026; version 2.17 | 2026-09-17 | regulator-confirmed |
| R21-C527 | No funded chronic weight-management benefit was found in Ontario semaglutide, tirzepatide and liraglutide searches; Sevmia and Wegovy appear only as off-formulary interchangeable entries. | formulary.health.gov.on.ca/formulary/results.xhtml?q=sema... | edition effective 2026-08-31; last updated 02/09/2026; version 2.17 | 2026-09-17 | unknown |
| R21-C558 | Ontario EAP reimbursable-product price listing: Imcivree DIN 02537745, 1 mL vial pack, 10 mg/mL, drug benefit price CAD 4022.9046, effective 2025-10-10. | ontario.ca/page/exceptional-access-program-product-prices | Updated 2026-08-31 | 2026-09-17 | regulator-confirmed |
| R21-C559 | Ontario EAP reimbursable-product price listing: Xenical DIN 02240325, 120 mg capsule, drug benefit price CAD 1.9606, effective 2026-03-31. | ontario.ca/page/exceptional-access-program-product-prices | Updated 2026-08-31 | 2026-09-17 | regulator-confirmed |
| R21-C560 | Xenical EAP criteria concern type 2 diabetes: HbA1c above 7% despite maximal oral diabetes medicines, BMI at least 27, and failed diet/nutritional counselling plus exercise. Initial approval is one year; first renewal is 12 months with at least 5% weight loss and HbA1c below 7% or reduction over 0.5%. | ontario.ca/files/moh-frequently-requested-drugs.pdf | 2025-01-01 cover date | 2026-09-17 | regulator-confirmed |
| R21-C561 | Imcivree/setmelanotide criteria were not found in the 484-page January 1, 2025 Frequently Requested Drugs PDF. | ontario.ca/files/moh-frequently-requested-drugs.pdf | 2025-01-01 cover date | 2026-09-17 | unknown |
| R21-C562 | Ontario EAP requires ODB eligibility and a funded drug/indication; its linked published criteria cover only some EAP drugs and do not guarantee approval. | ontario.ca/page/exceptional-access-program | Updated 2026-09-15 | 2026-09-17 | regulator-confirmed |
| A-C25 | RAMQ lists semaglutide brands/generics as exception medications | ramq.gouv.qc.ca/fr/citoyens/assurance-medicaments/savoir-... | Live record observed 2026-09-16 | 2026-09-16 | directly observed |
| R21-C546 | RAMQ search lists Apo-Semaglutide02568012/02568020 and Semaglutide Injection02567806/02567814 as Médicament d’exception. | ramq.gouv.qc.ca/fr/citoyens/assurance-medicaments/savoir-... | date not shown; current legal list effective 2026-08-27 | 2026-09-17 | regulator-confirmed |
| R21-C547 | RAMQ legal list effective August27 2026 has separate semaglutide and semaglutide(generic) headings; generic DINs02567806,02568012,02567814,02568020 are listed. Cross-brand Ozempic interchangeability not established from these headings. | ramq.gouv.qc.ca/sites/default/files/documents/non_indexes... | effective 2026-08-27 | 2026-09-17 | regulator-confirmed |
| R21-C548 | RAMQ semaglutide exception criterion treats T2DM with metformin where sulfonylurea is contraindicated, not tolerated or ineffective; injected reimbursement ceiling1mg weekly and oral14mg daily. | ramq.gouv.qc.ca/sites/default/files/documents/non_indexes... | effective 2026-08-27 | 2026-09-17 | regulator-confirmed |
| R21-C549 | A weight-management benefit was not established from the RAMQ semaglutide search and legal-list sections checked; searches for Imcivree/setmelanotide did not produce an extracted match. | ramq.gouv.qc.ca/sites/default/files/documents/non_indexes... | effective 2026-08-27 | 2026-09-17 | unknown |
| R21-C567 | The RAMQ covered-drug live search for Wegovy returned no result on September 17, 2026. | ramq.gouv.qc.ca/fr/citoyens/assurance-medicaments/savoir-... | No page update date displayed | 2026-09-17 | directly observed |
| R21-C568 | The RAMQ covered-drug live search for Saxenda returned no result on September 17, 2026. | ramq.gouv.qc.ca/fr/citoyens/assurance-medicaments/savoir-... | No page update date displayed | 2026-09-17 | directly observed |
| R21-C569 | The RAMQ covered-drug live search for Zepbound returned no result on September 17, 2026. | ramq.gouv.qc.ca/fr/citoyens/assurance-medicaments/savoir-... | No page update date displayed | 2026-09-17 | directly observed |
| R21-C570 | The RAMQ covered-drug live search for Sevmia returned no result on September 17, 2026. | ramq.gouv.qc.ca/fr/citoyens/assurance-medicaments/savoir-... | No page update date displayed | 2026-09-17 | directly observed |
| R21-C571 | The RAMQ covered-drug live search for Poviztra returned no result on September 17, 2026. | ramq.gouv.qc.ca/fr/citoyens/assurance-medicaments/savoir-... | No page update date displayed | 2026-09-17 | directly observed |
| A-C26 | NB historical bulletins describe Ozempic T2D SA; 2026 current criteria inaccessible | www2.gnb.ca/content/dam/gnb/Departments/h-s/pdf/en/NBDrug... | 2024 | 2026-09-16 | unknown |
| R21-C528 | The supplied old New Brunswick SA criteria URL returned 404 Not Found; a later web attempt returned Internal Error. A current replacement was found through the official NB Drug Plans formulary page. | www2.gnb.ca/content/dam/gnb/Departments/h-s/pdf/en/NBDrug... | not available | 2026-09-17 | directly observed |
| R21-C529 | New Brunswick current SA criteria PDF is dated September10 2026. Ozempic semaglutide 2 mg/1.5 mL, 2 mg/3 mL and 4 mg/3 mL autoinjectors are listed for adult T2DM added to metformin, or metformin plus sulfonylurea, when glycemic control is inadequate. | gnb.ca/content/dam/GNB3/t/hw-sme/nb-drug-plans/docs/speci... | 2026-09-10 | 2026-09-17 | regulator-confirmed |
| R21-C530 | NB Ozempic criteria require details of metformin contraindication/intolerance if applicable and a recent HbA1c; inadequate control is HbA1c at least7%. Claims maximum one autoinjector every4weeks. | gnb.ca/content/dam/GNB3/t/hw-sme/nb-drug-plans/docs/speci... | 2026-09-10 | 2026-09-17 | regulator-confirmed |
| R21-C531 | Liraglutide, Victoza and Saxenda were not found in the text of the current136-page NB SA criteria PDF. | gnb.ca/content/dam/GNB3/t/hw-sme/nb-drug-plans/docs/speci... | 2026-09-10 | 2026-09-17 | unknown |
| A-C27 | NS September 2026 exception criteria list restricted T2D Ozempic/generic and Rybelsus coverage | novascotia.ca/dhw/Pharmacare/documents/Criteria-for-Excep... | 2026-09 | 2026-09-16 | directly observed |
| R21-C550 | Nova Scotia September2026 formulary lists DrReddy02567806 with Ozempic02471477; Apo02568020 with Ozempic02540258; Apo02568012 and DrReddy02567814 with Ozempic02471469; all seven display interchangeabilityY and exception statusE. | novascotia.ca/sites/default/files/documents/1-3839/formul... | September 2026 | 2026-09-17 | regulator-confirmed |
| R21-C551 | Nova Scotia exception criteria cover Ozempic and generic brands for T2DM after inadequate control with metformin and sulfonylurea; maxone pen every4weeks. Imcivree has weight-management exception criteria for BBS adult/pediatric age6years and older. | novascotia.ca/dhw/Pharmacare/documents/Criteria-for-Excep... | September 2026 | 2026-09-17 | regulator-confirmed |
| A-C28 | Posted PEI semaglutide SA form specifies T2D prerequisites and one pen per four weeks | princeedwardisland.ca/sites/default/files/forms/semagluti... | 2024-11 form; current posted | 2026-09-16 | directly observed |
| R21-C552 | PEI August2026 formulary lists generic semaglutide02567806,02568020,02567814,02568012 under SA with program codesDNQW; semaglutide criteria explicitly say Ozempic and generics. | princeedwardisland.ca/sites/default/files/07dd/pei_pharma... | updated August 2026 | 2026-09-17 | regulator-confirmed |
| R21-C553 | PEI formulary explicitly states it is not to be used to determine interchangeability of therapeutic products; Ozempic-generic interchangeability was not established by the sources checked. | princeedwardisland.ca/sites/default/files/07dd/pei_pharma... | updated August 2026 | 2026-09-17 | unknown |
| R21-C554 | PEI August2026 formulary lists Imcivree02537745 under SA, program codesMNQW, for weight management of BBS obesity in adults and children6years and older. | princeedwardisland.ca/sites/default/files/07dd/pei_pharma... | updated August 2026 | 2026-09-17 | regulator-confirmed |
| R21-C555 | PEI semaglutide SA form covers T2DM with metformin plus sulfonylurea after inadequate glycemic control; asks for at least6months metformin and limits claims to one pen per4weeks. No date is printed on opened form. | princeedwardisland.ca/sites/default/files/forms/semagluti... | date not shown on form | 2026-09-17 | regulator-confirmed |
| A-C29 | NL SA portal links current criteria dated August 12, 2026 | gov.nl.ca/hcs/prescription/covered-specialauthdrugs/ | 2026-08-12 criteria date | 2026-09-16 | directly observed |
| R21-C532 | NL SA landing page links an August2026 criteria PDF described as updated August12 2026; Ozempic section within is updated July2026 and Rybelsus section May2026. | gov.nl.ca/hcs/prescription/covered-specialauthdrugs/ | download described as updated 2026-08-12 | 2026-09-17 | regulator-confirmed |
| R21-C533 | NL Ozempic criteria explicitly include generics; injectable semaglutide for T2DM with metformin after inadequate control on diet/exercise/metformin, or documented metformin contraindication/intolerance. Entry updated July2026. | gov.nl.ca/hcs/files/Criteria-Aug-2026.pdf | August 2026; Ozempic entry updated July 2026; Rybelsus entry updated May 2026 | 2026-09-17 | regulator-confirmed |
| R21-C534 | NL T2DM-only coverage allows at most one agent among DPP-4 inhibitors, SGLT2 inhibitors and GLP-1 agonists and does not fund concurrent oral/injectable semaglutide; injectable semaglutide reimbursement maximum1mg onceweekly. | gov.nl.ca/hcs/files/Criteria-Aug-2026.pdf | August 2026; Ozempic entry updated July 2026; Rybelsus entry updated May 2026 | 2026-09-17 | regulator-confirmed |
| R21-C535 | NL Rybelsus3,7,14mg tablet SA entry updated May2026 is for T2DM with metformin after inadequate control and includes the same combination restrictions. | gov.nl.ca/hcs/files/Criteria-Aug-2026.pdf | August 2026; Ozempic entry updated July 2026; Rybelsus entry updated May 2026 | 2026-09-17 | regulator-confirmed |
| A-C30 source 1 of 3 | Yukon no-cost national pharmacare excludes GLP-1s while other programmes may apply | yukon.ca/en/health-and-wellness/care-services/learn-about... | Current 2026 | 2026-09-16 | directly observed |
| A-C30 source 2 of 3 | NWT Pharmacare formulary includes restricted T2D Ozempic entry | hss.gov.nt.ca/en/services/nt-pharmacare-formulary | 2026-08-01 effective | 2026-09-16 | directly observed |
| A-C30 source 3 of 3 | Nunavut EHB eligibility and NIHB route differ; product-level coverage unextracted | gov.nu.ca/en/health/extended-health-benefits | Undated current page | 2026-09-16 | directly observed |